To review the available literature regarding the use of melatonin in the treatment of tardive dyskinesia (TD).
DATA SOURCES:
Literature was identified through MEDLINE (1966–September 2002), PsycINFO (1967–September 2002), and references of relevant articles. Review articles, case reports/series, and animal and human studies were reviewed.
DATA SYNTHESIS:
Melatonin has been investigated in TD based on its antioxidant properties. Animal studies and several human case series describe an association between melatonin and TD. Two recent, controlled studies evaluated the role of melatonin in the treatment of TD.
CONCLUSIONS:
There is a paucity of data evaluating the use of melatonin in TD. Both of the controlled studies evaluating its use are limited by methodologic issues. Although the most recent trial did report a statistically significant improvement in TD with melatonin, these results are not considered to be clinically significant. There are inadequate data at the present time to support the use of melatonin in patients with TD.
Other conditions that may be a focus of clinical attention. In: Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000: 736, 803–5.
BarakYSwartzMShamirESteinDWeizmanA. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia. Ann Clin Psychiatry1998; 10: 101–5.
12.
AdlerLARotrosenJEdsonRLavoriMAPLohrJHitzemannR, , and the Veterans Affairs Cooperative Study 394 Study Group. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry1999; 56: 836–41.
13.
GoffDCRenshawPFSarid-SegalODreyfussDAAmicoETCirauloA. A placebo-controlled trial of selegiline (L-Deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry1993; 33: 700–6.
14.
ReiterRJTanDXCabreraJD'ArpaDSainzRMMayoJC, The oxidant/antioxidant network: role of melatonin. Biol Signals Recept1999; 8: 56–63.
15.
RaghavendraVNaiduPSKulkarniSK. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. Brain Res2001; 904: 149–52.
16.
AbilioVCVeraJARJrFerreiraLSMDuarteCRMCarvalhoRCGrasslC, Effects of melatonin on orofacial movements in rats. Psychopharmacology2002; 161: 340–7.
17.
SandykR. The association of pineal calcification with drug-induced dystonic movements. Int J Neurosci1990; 53: 217–22.
18.
SandykRKaySR. The relationship of pineal calcification and melatonin secretion to the pathophysiology of tardive dyskinesia and Tourette's syndrome. Int J Neurosci1991; 58: 215–47.
19.
SandykR. The relationship of pineal calcification to subtypes of tardive dyskinesia in bipolar patients. Int J Neurosci1990; 54: 307–13.
20.
SandykRPardeshiR. Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. Int J Neurosci1990; 50: 215–21.
21.
SandykR. Tardive dyskinesia associated with depression in a bipolar patient: possible role of melatonin. Int J Neurosci1990; 52: 79–83.
22.
ZisapelNLaudonM. Inhibition by melatonin of dopamine release from rat hypothalamus. Brain Res1983; 272: 378–81.
23.
GiladiNShabtaiH. Melatonin-induced withdrawal emergent dyskinesia and akathisia. Movement Dis1999; 14: 381–2.
24.
ShamirEBarakYPlopskyIZisapelNElizurAWeizmanA. Is melatonin effective for tardive dyskinesia?J Clin Psychiatry2000; 61: 556–8.
25.
ShamirEBarakYShalmanILaudonMZisapelNTarraschR, Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry2001; 58: 1049–52.
26.
LlrocaPMChereauIBayleFJLanconC. Tardive dyskinesia and antipsychotics: a review. Eur Psychiatry2002; 17: 129–38.
27.
LohrJBCaligiuriMP. A double-bind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry1996; 57: 167–73.
28.
GlazerWMNaftolinFMorgensternHBarneaERMacLuskyNJBrennerLM. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology1985; 10: 345–50.
